Investigational Drug Information for delgocitinib
✉ Email this page to a colleague
What is the development status for investigational drug delgocitinib?
delgocitinib is an investigational drug.
There have been 15 clinical trials for delgocitinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 5th 2023.
The most common disease conditions in clinical trials are Eczema, Dermatitis, Atopic, and Dermatitis. The leading clinical trial sponsors are LEO Pharma and [disabled in preview].
There is one US patent protecting this investigational drug and forty-three international patents.
Summary for delgocitinib
| US Patents | 1 |
| International Patents | 43 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 34 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 2 (2023-09-05) |
| Vendors | 30 |
Recent Clinical Trials for delgocitinib
| Title | Sponsor | Phase |
|---|---|---|
| A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema | LEO Pharma | Phase 3 |
| Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema | LEO Pharma | Phase 1 |
| Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema | LEO Pharma | Phase 3 |
Clinical Trial Summary for delgocitinib
Top disease conditions for delgocitinib
Top clinical trial sponsors for delgocitinib
US Patents for delgocitinib
International Patents for delgocitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| delgocitinib | Argentina | AR077497 | 2029-07-31 | ⤷ Sign Up |
| delgocitinib | Australia | AU2010278066 | 2029-07-31 | ⤷ Sign Up |
| delgocitinib | Brazil | BR112012002157 | 2029-07-31 | ⤷ Sign Up |
| delgocitinib | Canada | CA2767899 | 2029-07-31 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
